An injectable preparation containing imipenem and preparation method thereof
Through freeze-thaw cycle technology and nanoparticle technology, a stable 'core-shell' structure is formed, which solves the problem of instability of imipenem in vivo, significantly improves its stability and rehydration performance, and ensures the therapeutic effect .
Patent Information
- Application Number
- CN202411164089.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-23
AI Technical Summary
The instability and metabolic pathways of imipenem in the body lead to its rapid degradation in the kidneys, affecting the therapeutic effect, and a good injectable preparation is needed to overcome this problem.
Using freeze-thaw cycle technology and nanoparticle technology, a stable 'core-shell' structure is formed by modifying the combination of distearyl phosphatidylglycerol, chitosan-thiol polyphosphate nanoparticles and sodium polyphosphate, and strengthening the The physical and chemical stability of the drug, and nanoparticles are formed through emulsion-curing technology, tightly encapsulating imipenem molecules and isolating external damage.
It significantly improves the physical and chemical stability of imipenem, reduces the risk of drug degradation, extends the validity period, ensures rapid and complete rehydration and efficient absorption of drugs, and improves the safety and effectiveness of treatment.
Smart Images

Figure CN118662458B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to an injectable preparation containing imipenem and a preparation method thereof. Background Art
[0002] In the field of modern medicine, with the increasing bacterial resistance, the search for highly effective, broad-spectrum antibiotics that can cope with multidrug resistance mechanisms has become an urgent need in the field of global public health. Imipenem, as a widely used carbapenem antibiotic in clinical practice, has become one of the first choice drugs for the treatment of severe bacterial infections such as sepsis, hospital-acquired pneumonia and complicated urinary tract infections due to its excellent antibacterial spectrum coverage and strong killing effect on many refractory Gram-positive and Gram-negative strains. Its unique structure gives it the ability to penetrate the bacterial cell wall and effectively inhibit bacterial cell wall synthesis, leading to bacterial death.
[0003] However, imipenem also faces severe challenges in clinical application, among which the most prominent problem is its instability and metabolic pathway in the body. Especially during the excretion process through the kidneys, if there are no appropriate protective measures, it is very susceptible to rapid degradation by dehydropeptidases in the kidneys, resulting in a decrease in blood drug concentration and affecting the therapeutic effect. To overcome this problem, scientists introduced the auxiliary ingredient of cilastatin sodium, which can specifically inhibit the activity of dehydropeptidases, effectively protect imipenem from enzymatic hydrolysis, and ensure that its biological activity in the body is maintained, thereby improving the safety and effectiveness of treatment. Therefore, based on the above problems, it is extremely necessary to develop an injectable preparation of imipenem with good stability and high efficiency. Summary of the invention
[0004] In view of the defects of the prior art, the object of the present invention is to provide an injectable preparation containing imipenem and a preparation method thereof.
[0005] The technical effect described in the present invention is achieved through the following technical scheme: an injectable preparation containing imipenem, which consists of imipenem, cilastatin sodium, modified distearoylphosphatidylglycerol, phytosterols, an emulsifier and a cryoprotectant.
[0006] Preferably, the preparation steps of the modified distearoylphosphatidylglycerol are as follows:
[0007] A1: Dissolve distearoylphosphatidylglycerol in 10 times the mass volume of anhydrous dimethylformamide solution, stir to dissolve evenly, then place in an ice bath, slowly add N-hydroxysuccinimide-maleimide ester, and then add diisopropylethylamine. After all reagents are added, stand at room temperature and under nitrogen protection for 6 to 12 hours, centrifuge, filter, wash with anhydrous ethanol, and vacuum freeze-dry at -40°C to obtain modified distearoylphosphatidylglycerol.
[0008] Preferably, the ratio of the amount of distearoylphosphatidylglycerol, N-hydroxysuccinimide-maleimide ester and diisopropylethylamine used in step A1 is 8g:3-4.5g:0.15-0.3mL; the N-hydroxysuccinimide-maleimide ester is prepared by reacting maleimide and N-hydroxysuccinimide in a molar mass ratio of 1:1.2 under anhydrous conditions.
[0009] Preferably, the emulsifier is any one of polysorbate-80, soy lecithin and poloxamer 188.
[0010] Preferably, the cryoprotectant is chitosan-thiol polyphosphate nanoparticles, and the specific preparation steps are as follows:
[0011] B1: Add chitosan to 30-50 times the mass volume of 0.1M NaOH solution, heat treat at 40-50°C for 2h, adjust to neutral with HCL solution, filter, wash, and dry to obtain pretreated chitosan; add polyvinyl alcohol to 30 times the mass volume of deionized water, heat to 60°C in a water bath, stir to dissolve evenly, then slowly add 2-mercaptoethanol dropwise under nitrogen protection and room temperature, adjust the pH to 7-7.5, stir for 15-30min, stand at 30-50°C for 6-12h, centrifuge, and dialyze with 0.22μm ultrafiltration to obtain thiol-polyvinyl alcohol;
[0012] B2: Dissolve the thiol-polyvinyl alcohol prepared in step B1 in 20 times the mass volume of deionized water, slowly add 10-20% of the mass of the substrate sodium trimetaphosphate, stir and mix evenly, adjust the pH to 7-9 with NaOH solution, then add 0.5wt% of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, stir evenly, add 0.3wt% of N-hydroxysuccinimide, and then react at 30-40°C for 6-12h under nitrogen protection to obtain a mixed solution;
[0013] B3: The pretreated chitosan prepared in step B1 is added to deionized water to prepare a 1wt% chitosan solution; then 2wt% glutaraldehyde and the mixed solution prepared in step B2 are added to the chitosan solution, ultrasonically treated at 30W for 10 to 30min, then gradually heated to 30 to 50°C within 30min, allowed to react for 1 to 1.5h, centrifuged at 8000rpm for 30min, filtered, and vacuum freeze-dried at -40°C to obtain chitosan-thiol polyphosphate nanoparticles.
[0014] Preferably, the mass ratio of the polyvinyl alcohol to 2-mercaptoethanol in step B1 is 1 g: 0.005-0.01 mL.
[0015] Preferably, the volume ratio of the chitosan solution to the mixed solution in step B3 is 1:1 to 1.5.
[0016] Preferably, another aspect of the present invention is to provide a method for preparing an injectable preparation containing imipenem, and the specific preparation steps are as follows:
[0017] S1: Under sterile conditions, imipenem, cilastatin sodium and an emulsifier are added to deionized water, the pH is adjusted to 7.5, and the mixture is stirred until uniformly dispersed to obtain a mixed solution A; phytosterols and modified distearoylphosphatidylglycerol are added to deionized water, and the mixture is fully stirred and mixed at 60-80° C. to obtain a mixed solution B;
[0018] S2: slowly drop the mixed solution A prepared in step S1 into the mixed solution B within 10 to 20 minutes, stirring at 200 to 300 rpm during the dropping process, and after the mixed solution A is added, increase the speed to 800 to 1000 rpm and stir for 10 to 30 minutes, filter with a 0.22 μm filter membrane, then add 0.1 wt% cryoprotectant, and perform ultrasonic treatment at 30 W for 10 minutes to obtain an emulsion;
[0019] S3: The emulsion prepared in step S2 is gradually cooled to -20 to -40°C at a rate of 2°C / min, frozen until completely solidified, and then moved to a 4°C refrigerated environment to slowly thaw naturally, and then the above freeze-thaw operation is repeated 3 to 5 times. After all freeze-thaw cycles are completed, a vacuum freeze-drying treatment at -40°C is performed to obtain an injectable preparation.
[0020] Preferably, in step S1, the ratio of imipenem, cilastatin sodium, emulsifier and deionized water is 50-100 mg: 50-100 mg: 1-2 mg: 20 mL; the ratio of phytosterol, modified distearoylphosphatidylglycerol and deionized water is 5-10 mg: 10 mg: 10 mL.
[0021] Preferably, the volume ratio of the mixed solution A to the mixed solution B in step S2 is 1:1 to 1.2.
[0022] The beneficial effects of the present invention are as follows:
[0023] The present invention introduces a freeze-thaw cycle process when preparing a freeze-dried imipenem injection, improves the recrystallization quality of the drug through multiple freeze-thaw cycles, optimizes the physical stability of the drug, reduces precipitation or crystallization during injection, and thus improves the long-term stability of the product. The present invention grafts thiol groups on polyvinyl alcohol (PVA) through a chemical reaction, which not only enhances the antioxidant capacity of the system - the thiol groups can effectively remove free radicals and resist oxidative stress, but also the natural water solubility and excellent film-forming properties of PVA help to improve the stability and rehydration performance of the freeze-dried product; further, polyphosphate (sodium trimetaphosphate) is incorporated to provide a metal ion chelating function, effectively inhibit metal-catalyzed drug degradation, and protect the structural integrity of imipenem during preparation and storage. Using emulsification-solidification technology, chitosan, modified thiol-polyvinyl alcohol and sodium trimetaphosphate are combined to form nanoparticles with high encapsulation ability. These nanoparticles not only tightly wrap the imipenem molecules to form a stable "core-shell" structure, effectively isolating the damage to external drug molecules during ice crystal formation, but also further promote the stability and bioavailability of the drug by increasing the surface area. In addition, the polysaccharide properties of chitosan and the modified thiol-polyvinyl alcohol jointly create a relatively constant microenvironment, which reduces the impact of water contact and pH fluctuations caused by freeze-thaw on the drug, and provides an additional protective barrier for imipenem. The modified distearoylphosphatidylglycerol contains maleimide groups, which are highly reactive and can covalently bind to the thiol groups on the surface of chitosan-thiol polyphosphate nanoparticles during the formation of nanoparticles, enhancing the membrane strength and stability of the nanoparticles. This covalent binding helps to reduce drug leakage and improve physical stability during freeze-drying and rehydration.
[0024] The freeze-thaw cycle technology and nanoparticles effectively play a synergistic role. The freeze-thaw cycle technology physically improves solubility and stability; the nanoparticles further consolidate the isolation between drug molecules during the freeze-drying stage to prevent aggregation and structural denaturation. The two effectively cooperate to greatly enhance the physical and chemical stability of the preparation. In addition, the freeze-thaw cycle reduces the formation of large ice crystals, and the nanoparticles further regulate the formation of ice crystals, synergistically reducing the physical damage of ice crystals to the drug; this process not only maintains the microstructure of imipenem, but also ensures the rapid and complete rehydration of the preparation, ensuring the immediate release and efficient absorption of imipenem. Finally, the stable environment constructed by chitosan-thiol polyphosphate, combined with the synergistic effect of freeze-thaw cycle optimized dispersibility and traditional lyoprotectants, jointly creates highly stable storage conditions for drugs, prolongs the shelf life of the product and reduces the risk of degradation. The imipenem injectable preparation prepared by the present invention can also be used in a powder-liquid double-chamber bag dosage form to improve drug stability. This method simplifies the production process and reduces costs while also ensuring the feasibility of large-scale production and product quality. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings in the following description are only for the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0026] Figure 1 is a biocompatibility test diagram of the chitosan-thiol polyphosphate nanoparticles prepared in Examples 1 to 4;
[0027] Figure 2 is the FTIR infrared spectrum of the chitosan-thiol polyphosphate nanoparticles prepared in Example 2;
[0028] Figure 3 It is a stability test chart of the imipenem injectable preparations prepared in Examples 2 to 3 and Comparative Examples 1 to 2;
[0029] Figure 4 It is a recovery test chart of the imipenem injectable preparations prepared in Examples 2 to 3 and Comparative Examples 1 to 2 in the rehydration test. DETAILED DESCRIPTION
[0030] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them; based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. It should be noted that, unless otherwise specified, the raw materials involved in the present invention are purchased through conventional commercial channels.
[0031] Example 1: An injectable preparation containing imipenem, consisting of imipenem, cilastatin sodium, modified distearoylphosphatidylglycerol, phytosterol, an emulsifier and a cryoprotectant.
[0032] The specific preparation steps of an injectable preparation containing imipenem are as follows:
[0033] 1. Preparation of modified distearoylphosphatidylglycerol:
[0034] A1: Dissolve 16 g of distearoylphosphatidylglycerol in 160 mL of anhydrous dimethylformamide solution, stir to dissolve evenly, then place in an ice bath, slowly add 6 g of N-hydroxysuccinimide-maleimide ester, and then add 0.3 mL of diisopropylethylamine. After all reagents are added, stand at room temperature and under nitrogen protection for 6 hours, centrifuge, filter, wash with anhydrous ethanol, and freeze-dry in a vacuum at -40°C to obtain modified distearoylphosphatidylglycerol;
[0035] 2. Preparation of Chitosan-Mercaptopolyphosphate Nanoparticles:
[0036] B1: Add 10g chitosan to 300mL of 0.1M NaOH solution, heat treat at 40℃ for 2h, adjust to neutral with HCL solution, filter, wash, and dry to obtain pretreated chitosan; add 10g polyvinyl alcohol to 300mL deionized water, heat to 60℃ in a water bath, stir to dissolve evenly, then slowly add 0.05g 2-mercaptoethanol dropwise under nitrogen protection and room temperature, adjust pH to 7, stir for 15min, stand at 30℃ for 12h, centrifuge, and dialyze with 0.22μm ultrafiltration to obtain thiol-polyvinyl alcohol;
[0037] B2: Dissolve 10 g of the thiol-polyvinyl alcohol prepared in step B1 in 200 mL of deionized water, slowly add 1 g of sodium trimetaphosphate, stir and mix evenly, adjust the pH to 7 with NaOH solution, then add 1 g of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, stir evenly, add 0.6 g of N-hydroxysuccinimide, and then react at 30° C. for 12 h under nitrogen protection to obtain a mixed solution;
[0038] B3: The pretreated chitosan prepared in step B1 was added to deionized water to prepare a 1wt% chitosan solution; then 2mL of glutaraldehyde and 100mL of the mixed solution prepared in step B2 were added to 100mL of the chitosan solution, and ultrasonic treatment was performed at 30W for 10min, and then the temperature was gradually raised to 30°C within 30min, and the reaction was allowed to stand for 1h, centrifuged at 8000rpm for 30min, filtered, and vacuum freeze-dried at -40°C to obtain chitosan-thiol polyphosphate nanoparticles;
[0039] 3. Preparation of injectable preparations containing imipenem:
[0040] S1: Under sterile conditions, 500 mg of imipenem, 500 mg of cilastatin sodium and 10 mg of polysorbate 80 were added to 200 mL of deionized water, the pH was adjusted to 7.5, and the mixture was stirred until uniformly dispersed to obtain a mixed solution A; 50 mg of phytosterol and 100 mg of modified distearoylphosphatidylglycerol were added to 100 mL of deionized water, and the mixture was thoroughly stirred and mixed at 60° C. to obtain a mixed solution B;
[0041] S2: Slowly drop 100 mL of the mixed solution A prepared in step S1 into 100 mL of the mixed solution B within 10 min, stirring at 200 rpm during the dropping process. After the dropwise addition of the mixed solution A is completed, increase the speed to 800 rpm and stir for 30 min, filter with a 0.22 μm filter membrane, then add 0.2 g of chitosan-thiol polyphosphate nanoparticles, and perform ultrasonic treatment at 30 W for 10 min to obtain an emulsion;
[0042] S3: The emulsion prepared in step S2 is gradually cooled to -20°C at a rate of 2°C / min, frozen until completely solidified, and then moved to a 4°C refrigerated environment to slowly thaw naturally, and then the above freeze-thaw operation is repeated 3 times. After all freeze-thaw cycles are completed, a vacuum freeze-drying treatment at -40°C is performed to obtain an injectable preparation.
[0043] Example 2: An injectable preparation containing imipenem, consisting of imipenem, cilastatin sodium, modified distearoylphosphatidylglycerol, phytosterol, an emulsifier and a cryoprotectant.
[0044] The specific preparation steps of an injectable preparation containing imipenem are as follows:
[0045] 1. Preparation of modified distearoylphosphatidylglycerol:
[0046] A1: Dissolve 16 g of distearoylphosphatidylglycerol in 160 mL of anhydrous dimethylformamide solution, stir to dissolve evenly, then place in an ice bath, slowly add 8 g of N-hydroxysuccinimide-maleimide ester, and then add 0.5 mL of diisopropylethylamine. After all reagents are added, stand at room temperature and under nitrogen protection for 10 hours, centrifuge, filter, wash with anhydrous ethanol, and freeze-dry in a vacuum at -40°C to obtain modified distearoylphosphatidylglycerol;
[0047] 2. Preparation of Chitosan-Mercaptopolyphosphate Nanoparticles:
[0048] B1: 10 g of chitosan was added to 450 mL of 0.1 M NaOH solution, heat treated at 48 ° C for 2 h, then adjusted to neutral with HCL solution, filtered, washed, and dried to obtain pretreated chitosan; 10 g of polyvinyl alcohol was added to 300 mL of deionized water, heated to 60 ° C in a water bath, stirred and dissolved evenly, and then 0.09 mL of 2-mercaptoethanol was slowly added dropwise under nitrogen protection and room temperature, the pH was adjusted to 7.5, stirred for 25 min, and then allowed to stand at 50 ° C for 6 h, centrifuged, and dialyzed by 0.22 μm ultrafiltration to obtain thiol-polyvinyl alcohol;
[0049] B2: Dissolve 10 g of the thiol-polyvinyl alcohol prepared in step B1 in 200 mL of deionized water, slowly add 1.8 g of sodium trimetaphosphate, stir and mix evenly, adjust the pH to 8.5 with NaOH solution, then add 1 g of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, stir evenly, add 0.6 g of N-hydroxysuccinimide, and then react at 38° C. for 10 h under nitrogen protection to obtain a mixed solution;
[0050] B3: The pretreated chitosan prepared in step B1 was added to deionized water to prepare a 1wt% chitosan solution; then 2mL of glutaraldehyde and 140mL of the mixed solution prepared in step B2 were added to 100mL of the chitosan solution, and the mixture was ultrasonically treated at 30W for 20min, and then the temperature was gradually raised to 45°C within 30min, and the mixture was allowed to stand for 1.5h, centrifuged at 8000rpm for 30min, filtered, and vacuum freeze-dried at -40°C to obtain chitosan-thiol polyphosphate nanoparticles;
[0051] 3. Preparation of injectable preparations containing imipenem:
[0052] S1: Under sterile conditions, 800 mg of imipenem, 800 mg of cilastatin sodium and 18 mg of polysorbate 80 were added to 200 mL of deionized water, the pH was adjusted to 7.5, and the mixture was stirred until uniformly dispersed to obtain a mixed solution A; 80 mg of phytosterol and 100 mg of modified distearoylphosphatidylglycerol were added to 100 mL of deionized water, and the mixture was thoroughly stirred and mixed at 75°C to obtain a mixed solution B;
[0053] S2: Slowly drop 100 mL of the mixed solution A prepared in step S1 into 115 mL of the mixed solution B within 15 min, stirring at 280 rpm during the dropping process. After the dropwise addition of the mixed solution A is completed, increase the speed to 800 rpm and stir for 25 min, filter with a 0.22 μm filter membrane, then add 0.215 g of chitosan-thiol polyphosphate nanoparticles, and perform ultrasonic treatment at 30 W for 10 min to obtain an emulsion;
[0054] S3: The emulsion prepared in step S2 is gradually cooled to -40°C at a rate of 2°C / min, frozen until completely solidified, and then moved to a 4°C refrigerated environment to slowly thaw naturally, and then the above freeze-thaw operation is repeated 5 times. After all freeze-thaw cycles are completed, a vacuum freeze-drying treatment at -40°C is performed to obtain an injectable preparation.
[0055] Example 3: An injectable preparation containing imipenem, consisting of imipenem, cilastatin sodium, modified distearoylphosphatidylglycerol, phytosterol, an emulsifier and a cryoprotectant.
[0056] The specific preparation steps of an injectable preparation containing imipenem are as follows:
[0057] 1. Preparation of modified distearoylphosphatidylglycerol:
[0058] A1: Dissolve 16 g of distearoylphosphatidylglycerol in 160 mL of anhydrous dimethylformamide solution, stir to dissolve evenly, then place in an ice bath, slowly add 7.5 g of N-hydroxysuccinimide-maleimide ester, and then add 0.4 mL of diisopropylethylamine. After all reagents are added, stand at room temperature and under nitrogen protection for 8 h, centrifuge, filter, wash with anhydrous ethanol, and freeze-dry in a vacuum at -40°C to obtain modified distearoylphosphatidylglycerol;
[0059] 2. Preparation of Chitosan-Mercaptopolyphosphate Nanoparticles:
[0060] B1: Add 10g chitosan to 400mL of 0.1M NaOH solution, heat treat at 45℃ for 2h, adjust to neutral with HCL solution, filter, wash, and dry to obtain pretreated chitosan; add 10g polyvinyl alcohol to 300mL deionized water, heat to 60℃ in a water bath, stir to dissolve evenly, then slowly add 0.08mL of 2-mercaptoethanol dropwise under nitrogen protection and room temperature, adjust pH to 7.2, stir for 20min, stand at 45℃ for 8h, centrifuge, and dialyze with 0.22μm ultrafiltration to obtain thiol-polyvinyl alcohol;
[0061] B2: Dissolve 10 g of the thiol-polyvinyl alcohol prepared in step B1 in 200 mL of deionized water, slowly add 1.5 g of sodium trimetaphosphate, stir and mix evenly, adjust the pH to 8 with NaOH solution, then add 1 g of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, stir evenly, add 0.6 g of N-hydroxysuccinimide, and then react at 35 ° C for 8 h under nitrogen protection to obtain a mixed solution;
[0062] B3: The pretreated chitosan prepared in step B1 was added to deionized water to prepare a 1wt% chitosan solution; then 2mL of glutaraldehyde and 130mL of the mixed solution prepared in step B2 were added to 100mL of the chitosan solution, and the mixture was ultrasonically treated at 30W for 25min, and then the temperature was gradually raised to 40°C within 30min, and the mixture was allowed to stand for 1.2h, centrifuged at 8000rpm for 30min, filtered, and vacuum freeze-dried at -40°C to obtain chitosan-thiol polyphosphate nanoparticles;
[0063] 3. Preparation of injectable preparations containing imipenem:
[0064] S1: Under sterile conditions, 700 mg of imipenem, 700 mg of cilastatin sodium and 15 mg of soybean lecithin were added to 200 mL of deionized water, the pH was adjusted to 7.5, and the mixture was stirred until uniformly dispersed to obtain a mixed solution A; 70 mg of phytosterol and 100 mg of modified distearoylphosphatidylglycerol were added to 100 mL of deionized water, and the mixture was fully stirred and mixed at 70°C to obtain a mixed solution B;
[0065] S2: Slowly drop 100 mL of the mixed solution A prepared in step S1 into 105 mL of the mixed solution B within 15 min, stirring at 240 rpm during the dropping process. After the dropwise addition of the mixed solution A is completed, increase the speed to 900 rpm and stir for 20 min, filter with a 0.22 μm filter membrane, then add 0.205 g of chitosan-thiol polyphosphate nanoparticles, and perform ultrasonic treatment at 30 W for 10 min to obtain an emulsion;
[0066] S3: The emulsion prepared in step S2 is gradually cooled to -30°C at a rate of 2°C / min, frozen until completely solidified, and then moved to a 4°C refrigerated environment to slowly thaw naturally, and then the above freeze-thaw operation is repeated 4 times. After all freeze-thaw cycles are completed, a vacuum freeze-drying treatment at -40°C is performed to obtain an injectable preparation.
[0067] Example 4: An injectable preparation containing imipenem, consisting of imipenem, cilastatin sodium, modified distearoylphosphatidylglycerol, phytosterol, an emulsifier and a cryoprotectant.
[0068] The specific preparation steps of an injectable preparation containing imipenem are as follows:
[0069] 1. Preparation of modified distearoylphosphatidylglycerol:
[0070] A1: Dissolve 16 g of distearoylphosphatidylglycerol in 160 mL of anhydrous dimethylformamide solution, stir to dissolve evenly, then place in an ice bath, slowly add 9 g of N-hydroxysuccinimide-maleimide ester, and then add 0.6 mL of diisopropylethylamine. After all reagents are added, stand at room temperature and under nitrogen protection for 12 h, centrifuge, filter, wash with anhydrous ethanol, and freeze-dry in a vacuum at -40°C to obtain modified distearoylphosphatidylglycerol;
[0071] 2. Preparation of Chitosan-Mercaptopolyphosphate Nanoparticles:
[0072] B1: Add 10g chitosan to 500mL of 0.1M NaOH solution, heat treat at 50℃ for 2h, adjust to neutral with HCL solution, filter, wash, and dry to obtain pretreated chitosan; add 10g polyvinyl alcohol to 300mL deionized water, heat to 60℃ in a water bath, stir to dissolve evenly, then slowly add 0.1mL of 2-mercaptoethanol under nitrogen protection and room temperature, adjust pH to 7.5, stir for 30min, stand at 50℃ for 6h, centrifuge, and dialyze with 0.22μm ultrafiltration to obtain thiol-polyvinyl alcohol;
[0073] B2: Dissolve 10 g of the thiol-polyvinyl alcohol prepared in step B1 in 200 mL of deionized water, slowly add 2 g of sodium trimetaphosphate, stir and mix evenly, adjust the pH to 9 with NaOH solution, then add 1 g of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, stir evenly, add 0.6 g of N-hydroxysuccinimide, and then react at 40° C. for 6 h under nitrogen protection to obtain a mixed solution;
[0074] B3: The pretreated chitosan prepared in step B1 was added to deionized water to prepare a 1wt% chitosan solution; then 2mL of glutaraldehyde and 150mL of the mixed solution prepared in step B2 were added to 100mL of the chitosan solution, and ultrasonic treatment was performed at 30W for 30min, and then the temperature was gradually raised to 50°C within 30min, and the reaction was allowed to stand for 1.5h, centrifuged at 8000rpm for 30min, filtered, and vacuum freeze-dried at -40°C to obtain chitosan-thiol polyphosphate nanoparticles;
[0075] 3. Preparation of injectable preparations containing imipenem:
[0076] S1: Under sterile conditions, 1000 mg of imipenem, 1000 mg of cilastatin sodium and 20 mg of poloxamer 188 were added to 200 mL of deionized water, the pH was adjusted to 7.5, and the mixture was stirred until uniformly dispersed to obtain a mixed solution A; 100 mg of phytosterol and 100 mg of modified distearoylphosphatidylglycerol were added to 100 mL of deionized water, and the mixture was fully stirred and mixed at 80° C. to obtain a mixed solution B;
[0077] S2: Slowly drop 100 mL of the mixed solution A prepared in step S1 into 120 mL of the mixed solution B within 20 min, stirring at 300 rpm during the dropping process. After the dropwise addition of the mixed solution A is completed, increase the speed to 1000 rpm and stir for 10 min, filter with a 0.22 μm filter membrane, then add 0.22 g of chitosan-thiol polyphosphate nanoparticles, and perform ultrasonic treatment at 30 W for 10 min to obtain an emulsion;
[0078] S3: The emulsion prepared in step S2 is gradually cooled to -40°C at a rate of 2°C / min, frozen until completely solidified, and then moved to a 4°C refrigerated environment to slowly thaw naturally, and then the above freeze-thaw operation is repeated 5 times. After all freeze-thaw cycles are completed, a vacuum freeze-drying treatment at -40°C is performed to obtain an injectable preparation.
[0079] Comparative Example 1: Comparative Example 1 is substantially the same as Example 2, except that in Comparative Example 1, sucrose is used instead of chitosan-thiol polyphosphate nanoparticles as a freeze-drying protective agent.
[0080] Comparative Example 2: Comparative Example 2 is substantially the same as Example 3, except that the distearoylphosphatidylglycerol is not modified in Comparative Example 2.
[0081] Performance test: Biocompatibility test: The chitosan-thiol polyphosphate nanoparticles prepared in Examples 1 to 4 were placed at the bottom of the culture plate and evenly distributed in a 96-well plate with 8 wells per group of samples. 50 μL of DMEM medium was added to each well, and then L929 mouse fibroblasts were diluted to 1×10 4 / mL and then inoculate 50 μL in the wells added with samples. At the same time, 8 wells without samples were used as negative control groups, and 8 wells added with 10wt% dimethyl sulfoxide solution were used as positive control groups. The temperature was set at 37°C and 5% CO2. 5 μL of 5 mg / mL MTT solution was added after culturing for 24h, 72h, and 168h, respectively. After further culturing for 4h, the culture medium in the wells was aspirated, 50 μL of dimethyl sulfoxide was added to the wells, and the absorbance (OD value) was measured at 490nm using a microplate reader to measure the activity percentage [biocompatibility (%) = (OD value of the embodiment - OD value of the negative control group) / (OD value of the positive control group - OD value of the negative control group) × 100%], blank control group: only containing culture medium and MTT solution; negative control group: untreated cells were used as control; each sample was processed and analyzed three times, and the results were averaged. The results are shown in Figure 1 shown.
[0082] Depend on Figure 1 The results show that the chitosan-thiol polyphosphate nanoparticles prepared by the present invention have excellent biocompatibility, do not cause toxic damage to cells, and can be effectively used in the preparation of imipenem injectable preparations.
[0083] Spectrum test: The chitosan-thiol polyphosphate nanoparticles prepared in Example 2 were mixed with KBr powder and pressed into tablets. The spectrum was measured using an FTIR spectrometer. The results were as follows: Figure 2 shown.
[0084] Depend on Figure 2The results show that the FTIR spectrum shows obvious mercaptan wavelengths in the range of 2550-2600 cm -1 Peak, 1100–1200 cm of sodium trimetaphosphate -1 Peak and 950 cm -1 Peak, 3400 cm of chitosan -1 The broad peak effectively verifies the successful preparation of the chitosan-thiol polyphosphate nanoparticles of the present invention.
[0085] Stability test: The samples of the imipenem injectable preparations prepared in Examples 2 to 3 of the present invention and Comparative Examples 1 to 2 were sealed according to commercial packaging and placed at a temperature of 35 ± 5°C and a relative humidity of 75 ± 5% for 6 months. Samples were taken at the 1st, 2nd, 3rd and 6th month of the test period, and the imipenem drug content in the samples was detected by high performance liquid chromatography, and the stability was calculated [stability (%) = (imipenem sample content before the test - imipenem sample content in the nth month of the test) / imipenem sample content before the test × 100%]. The results are as follows: Figure 3 shown.
[0086] Depend on Figure 3 The results show that the imipenem injectable preparation prepared by the present invention has excellent stability after freeze-thaw cycle treatment and can be effectively stored for a long time. From the results of Comparative Example 1 and Example 2, it can be seen that when sucrose replaces chitosan-thiol polyphosphate nanoparticles as a freezing agent, the performance is lost and the stability of the injectable preparation decreases significantly in 6 months; the results of Comparative Example 2 and Example 3 show that distearoylphosphatidylglycerol replaces modified distearoylphosphatidylglycerol and undergoes phase change or aggregation during long-term storage, resulting in a more obvious impact on the stability of the imipenem injectable preparation.
[0087] Rehydration test: 50 mL of deionized water was added to the imipenem injectable preparation samples (500 mg) prepared in Examples 2 to 3 and Comparative Examples 1 to 2, and a rehydration test was performed at room temperature. The time from the addition of the solvent to the complete dissolution of the lyophilized preparation was recorded. The dissolution was observed and recorded at 0.5 min, 1 min, 5 min, 10 min, and 20 min. A turbidimeter (0 to 100 NTU, resolution 0.01 NTU) was used for testing. At the same time, the imipenem content before and after the sample test was calculated using high performance liquid chromatography (recovery rate (%) = drug content after rehydration / drug content before rehydration × 100%). Each sample was tested three times, and the results were averaged. The recovery test results are as follows: Figure 4 The dissolution record results are shown in Table 1 below (specific parameters:
[0088] Color change: 4 points: the color of the solution is exactly the same as the original solution; 3 points: the color of the solution has changed slightly; 2 points: the color of the solution has changed significantly; 1 point: the color of the solution has changed significantly.
[0089] Undissolved particles: 4 points: no undissolved particles in the solution; 3 points: very few tiny particles in the solution; 2 points: a small amount of visible particles in the solution; 1 point: a large amount of undissolved large particles in the solution.
[0090] Bubble generation: 4 points: no bubbles are generated in the solution; 3 points: very small amount of bubbles are generated in the solution, which does not affect observation; 2 points: a small amount of bubbles are generated in the solution, which affects observation; 1 point: a large amount of bubbles are generated in the solution, which seriously affects observation).
[0091] Table 1. Results of rehydration testing of imipenem injectable formulations.
[0092]
[0093] As shown in Table 1, the imipenem injectable preparation prepared by the present invention has excellent rehydration test results, excellent high efficiency and stability, no color change, no undissolved particles, and no bubbles. As shown in Table 1 and Example 2, compared with chitosan-thiol polyphosphate nanoparticles, sucrose does not have the same protective effect. Although the color change is not obvious, it is slightly turbid, and the difference in undissolved particles is more obvious. As shown in Table 1 and Example 3, the unmodified phospholipids cause the solution to be slightly turbid, and the generation of undissolved particles and bubbles is more obvious. Figure 4 The results show that the recovery rate of the imipenem injectable preparations prepared by the present invention after rehydration is much higher than 95%, and the preparations have excellent stability, and no significant drug loss is caused during the rehydration process. The results of Comparative Example 1 and Example 2 show that the replacement of chitosan-thiol polyphosphate nanoparticles with sucrose significantly affects the recovery rate of the preparations after rehydration.
[0094] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A method for preparing an injectable preparation containing imipenem, characterized in that: The injectable preparation containing imipenem consists of imipenem, cilastatin sodium, modified distearoylphosphatidylglycerol, phytosterol, emulsifier and cryoprotectant; The cryoprotectant is chitosan-thiol polyphosphate nanoparticles, and the specific preparation steps are as follows: B1: Add chitosan to NaOH solution, heat treat at 40-50°C, then adjust to neutral with HCl solution, filter, wash, and dry to obtain pretreated chitosan; add polyvinyl alcohol to deionized water, heat in a water bath, stir to dissolve evenly, then slowly add 2-mercaptoethanol dropwise under nitrogen protection and room temperature, adjust pH, stir for 15-30 minutes, stand for reaction, centrifuge, and ultrafilter to obtain thiol-polyvinyl alcohol; B2: dissolving the thiol-polyvinyl alcohol prepared in step B1 in deionized water, slowly adding sodium trimetaphosphate, stirring and mixing evenly, adjusting the pH with NaOH solution, and then adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, stirring evenly, adding N-hydroxysuccinimide, and then reacting under nitrogen protection for 6 to 12 hours to obtain a mixed solution; B3: adding the pretreated chitosan prepared in step B1 to deionized water to prepare a chitosan solution; then adding glutaraldehyde and the mixed solution prepared in step B2 to the chitosan solution, ultrasonically treating, then gradually heating to 30-50° C. within 30 min, standing to react, centrifuging, filtering, and vacuum freeze-drying to obtain chitosan-thiol polyphosphate nanoparticles; The preparation steps of the modified distearoylphosphatidylglycerol are as follows: A1: Dissolve distearoylphosphatidylglycerol in 10 times the mass volume of anhydrous dimethylformamide solution, stir to dissolve evenly, then place in an ice bath, slowly add N-hydroxysuccinimide-maleimide ester, and then add diisopropylethylamine. After all reagents are added, stand at room temperature and under nitrogen protection for 6 to 12 hours, centrifuge, filter, wash with anhydrous ethanol, and freeze-dry in a vacuum at -40°C to obtain modified distearoylphosphatidylglycerol; The mass ratio of polyvinyl alcohol to 2-mercaptoethanol in step B1 is 1 g: 0.005-0.01 mL; the volume ratio of chitosan solution to mixed solution in step B3 is 1: 1-1.5; The ratio of the amount of distearoylphosphatidylglycerol, N-hydroxysuccinimide-maleimide ester and diisopropylethylamine used in step A1 is 8g:3-4.5g:0.15-0.3mL; the N-hydroxysuccinimide-maleimide ester is prepared by reacting maleimide and N-hydroxysuccinimide at a molar mass ratio of 1:1.2 under anhydrous conditions; The emulsifier is any one of polysorbate-80, soy lecithin and poloxamer 188; The preparation method of the injectable preparation containing imipenem comprises the following specific preparation steps: S1: Under sterile conditions, imipenem, cilastatin sodium and an emulsifier are added to deionized water, the pH is adjusted to 7.5, and the mixture is stirred until uniformly dispersed to obtain a mixed solution A; phytosterols and modified distearoylphosphatidylglycerol are added to deionized water, and the mixture is stirred and mixed to obtain a mixed solution B; S2: slowly drop the mixed solution A prepared in step S1 into the mixed solution B, stirring at 200-300 rpm during the dropwise addition, and after the dropwise addition of the mixed solution A is completed, the speed is increased to 800-1000 rpm for stirring reaction, and after the reaction is completed, the mixture is filtered through a filter membrane, and then a cryoprotectant is added, and ultrasonic treatment is performed to obtain an emulsion; S3: The emulsion prepared in step S2 is gradually cooled to -20 to -40°C at a rate of 2°C / min, frozen until completely solidified, and then moved to a 4°C refrigerated environment to slowly thaw naturally, and then the above freeze-thaw operation is repeated 3 to 5 times. After all freeze-thaw cycles are completed, vacuum freeze-drying is performed to obtain an injectable preparation.
2. The method for preparing an injectable preparation containing imipenem according to claim 1, characterized in that: The ratio of the amount of imipenem, cilastatin sodium, emulsifier and deionized water in step S1 is 50-100 mg: 50-100 mg: 1-2 mg: 20 mL; the ratio of the amount of phytosterol, modified distearoylphosphatidylglycerol and deionized water is 5-10 mg: 10 mg: 10 mL; the volume ratio of the mixed solution A and the mixed solution B in step S2 is 1: 1-1.2.
